Skip to main content
Bern employee Adriano Marques)

R&D Respiratory

Respiratory

Chronic respiratory diseases impose an enormous burden on patients and society and are a leading cause of death and disability worldwide. To address this need, CSL is investigating new clinical treatments for respiratory diseases using our plasma derived immunoglobulins and proteins and novel recombinant monoclonal antibodies.

healthcare professionals

Alpha-1 Antitrypsin (AAT) deficiency is a hereditary condition that can severely affect the function of a patient’s lung. The condition is marked by a low level or absence of AAT, a natural protein that inhibits neutrophil elastase to prevent the destruction of lung tissue. Severe deficiency of AAT is associated with a strong tendency for the development of emphysema, a form of COPD, and can significantly impact everyday life and life expectancy of patients. Our plasma derived protein product has been proven to raise and maintain AAT serum levels in patients with AAT deficiency and clinical evidence of emphysema. 

In addition to our existing product ZEMAIRA®/RESPREEZA® for patients with AAT deficiency, CSL is investigating new clinical treatments for respiratory diseases using novel recombinant monoclonal antibodies and plasma derived therapies to address this need. We have developed a nebulized Immunoglobulin (Ig) formulation (CSL787) which may potentially reduce the frequency of respiratory infections or symptoms of chronic lung disease in patients with bronchiectasis and severe COPD - CSL787 is currently in Phase 1. Generally, immunoglobulins (Ig) are administered intravenously or subcutaneously. In our effort to innovate for patients, CSL is studying a new route of administration via aerosolized delivery to the respiratory tract. 

We are also developing a novel monoclonal antibody, CSL311, which neutralizes the ß-common receptor associated with the development of chronic inflammatory diseases. CSL311 is being investigated for the treatment of severe uncontrolled asthma and severe Chronic Obstructive Pulmonary Disease (COPD). In Idiopathic Pulmonary Fibrosis (IPF), a severe debilitating disease, we are planning to start a clinical development program with garadacimab, the first of our compounds being explored in this disease area.